drugset
drugset / Trial / NCT02271360

Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

NCT02271360 ↗

Phase 2/3 Completed 200 enrolled Benha University
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to compare the effect of oral Calcium Dobesilate to oral Cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent intracytoplasmic sperm injection (ICSI).

Timeline

Start
2014-04
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cabergoline Small molecule 0.5 mg Oral
Comparator Calcium Dobesilate Unknown 500 mg Oral

Indications

infertility disorder